JPRN-UMIN000009108
Recruiting
未知
A phase II neoadjuvant trial of concurrent trastuzumab, paclitaxel and endocrine therapy in women with HER2-positive and hormone receptor-positive breast cancer. - HERPLET
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Keio University School of Medicine
- Enrollment
- 50
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\. Other active malignancies 2\. Hemorrhagic diathesis 3\. History of cardiac infarction, valvular diseases of the heart and severe cardiac disfunction 4\. Liver cirrhosis 5\. Other medical conditions that could limit a patient's ability to undertake study therapy
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
A phase II neoadjuvant trial of concurrent trastuzumab and aromatase inhibitor in postmenopausal women with HER2-positive and hormone receptor-positive breast cancer.Postmenopausal women with HER2-positive and hormone receptor-positive breast cancer.JPRN-UMIN000007353Keio University School of Medicine50
Active, not recruiting
Not Applicable
Phase II Study of neoadjuvant therapy with trastuzumab plus docetaxel followed by trastuzumab plus pegylated liposomal doxorubicin and cyclophosphamide in human ErbB-2-positive operable or locally advanced breast cancer - CETRAOperable breast cancer patients or locally advanced breast cancer patients (stage II-III), with HER2 overexpression or gene amplificationMedDRA version: 9.1Level: LLTClassification code 10057654Term: Breast cancer femaleEUCTR2006-003993-85-ITISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE G. PASCALE
Active, not recruiting
Phase 1
A phase 2 clinical trial conducted investigate the effectiveness of trastuzumab deruxtecan (T-DXd) administered before surgery for the treatment of HER-2 positive breast cancer.HER2-positive breast cancer.MedDRA version: 23.0Level: PTClassification code 10065430Term: HER2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2022-002485-32-IECancer Trials Ireland80
Recruiting
Phase 3
A Phase 3 Trial of Neoadjuvant T-DXd Monotherapy or T-DXd followed by THP Compared to ddAC-THP in Participants with High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11)HER2-positive early breast cancerJPRN-jRCT2041210097Inoguchi Akihiro900
Active, not recruiting
Phase 3
Global open label phase-III study having 3 treatment arm in neoadjuvant setting in Patients with High-risk HER 2-positive Early-stage Breast CancerHealth Condition 1: C509- Malignant neoplasm of breast of unspecified siteCTRI/2022/01/039210ASTRAZENECA AB